Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Targeted inhibition of IL-6 signalling withtocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs 71st Annual Scientific Meeting of the American-College-of-Rheumatology/42nd Association-of-Rheumatology-Health-Professionals Gomez-Reino, J. J., FAIRFAX, M. J., Pavelka, K., Alecock, E., Woodworth, T., Genovese, M. WILEY-LISS. 2007: 4234–34
View details for Web of Science ID 000251781200051